News


All series


All News

Abemaciclib, the only CDK4/6 inhibitor approved as a single-agent, has amassed several clinical indications for patients with metastatic breast cancer. The findings from the phase III MONARCH2 and 3 trials, as well as the phase II MONARCH1 study led to these approvals. Each trial showed improvements in progression-free survival, especially in patients with visceral disease and endocrine therapy resistance.

Presented at the 2018 Miami Breast Cancer Conference, results from the phase III OlympiAD trial demonstrated improvements in progression-free survival with olaparib over treatment of physician&#39;s choice. These results were consistent regardless of the baseline tumor burden for patients with HER2-negative breast cancer with a germline <em>BRCA</em>1/2 mutation.

Frederick M. Schnell, MD, has been appointed to the newly created position of medical director at the Community Oncology Alliance. With over 30 years of experience as a physician and CEO of a community oncology practice, Schnell plans to reform the future of oncology payment.

Based on data&nbsp;from the phase III S-TRAC trial,<span style="font-size:10.8333px"> </span>the&nbsp;European Medicines Agency&rsquo;s Committee for Medicinal Products for Human Use recently recommended against approving&nbsp;sunitinib for use as an adjuvant therapy in patients with renal cell carcinoma who have received nephrectomy and are high risk for recurrence.

According to results from the CALGB 8903 study published in the <em>Journal of Clinical Oncology, </em>there is an association between total nut intake and improved outcomes in patients with stage III colon cancer. Results of the study showed patients who ate at least 2 servings of nuts per week had superior disease-free survival and overall survival.

A novel regimen of immunotherapy, angiogenesis inhibition, and chemotherapy brings promising outcomes for patients with non-small cell lung cancer (NSCLC). The synergic combination, notes Benjamin P. Levy, MD, would be exciting to have in the landscape.